Dihydroxyacetone phosphate
- Generic Name
- Dihydroxyacetone phosphate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C3H7O6P
- CAS Number
- 57-04-5
- Unique Ingredient Identifier
- T7KF2T6W95
- Background
Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
- Associated Conditions
- -
- Associated Therapies
- -
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Marjolein Spiering
- Target Recruit Count
- 72
- Registration Number
- NCT02280993
- Locations
- 🇫🇷
Centre Hospitalier et Universitaire, Nantes, France
🇫🇷Centre Hospitalier Universitaire, Lille, France
🇳🇱University Medical Center Groningen, Groningen, Netherlands
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
- Conditions
- Interventions
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01626664
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇫🇷Hospital Necker, Paris, France
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 73
- Registration Number
- NCT01453504
- Locations
- 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 187
- Registration Number
- NCT01453205
- Locations
- 🇹🇷
Research Site, Talas, Turkey
Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
- Conditions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2006-10-06
- Lead Sponsor
- University of Magdeburg
- Target Recruit Count
- 30
- Registration Number
- NCT00384553
- Locations
- 🇩🇪
University of Magdeburg, Magdeburg, Germany
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00003143
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.